When access is an issue: exploring barriers to predictive testing for Huntington disease in British Columbia, Canada

Alice K Hawkins1, Susan Creighton, Michael R Hayden

  • 1Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada. alicehaw@exchange.ubc.ca

Insights

Predictive testing for Huntington disease (HD) is often inaccessible due to distance and inflexible scheduling, preventing at-risk individuals from accessing crucial genetic services and support.

Area of Science:

  • Genetics
  • Public Health
  • Healthcare Accessibility

Background:

  • Predictive testing (PT) for Huntington disease (HD) involves multiple in-person appointments.
  • Current PT accessibility issues may prevent at-risk individuals from receiving potential benefits.

Purpose of the Study:

  • To investigate accessibility barriers to PT for Huntington disease (HD).
  • To explore potential solutions for improving PT service delivery.

Main Methods:

  • An interview study was conducted with individuals at risk for HD in British Columbia, Canada.
  • Qualitative data were gathered to understand patient perspectives on PT access.

Main Results:

  • Accessibility barriers to PT include structural issues (distance, travel time, costs) and process inflexibility (emotional/psychological access).
  • These barriers deter individuals from obtaining essential support, information, and counseling.
  • Inflexible PT processes and geographical distance limit access to genetic services.

Conclusions:

  • Creative and adaptable solutions are needed to personalize the delivery of genetic services.
  • Improving access to PT is crucial for enhancing quality of life and preventing healthcare inequities.
  • Rethinking service delivery can address access barriers and ensure equitable healthcare for individuals at risk of HD.

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...